Skip to main content
Top

Open Access 23-04-2024 | Respiratory Microbiota | REVIEW

Modulation of Gut Microbiota Through Dietary Intervention in Neuroinflammation and Alzheimer’s and Parkinson’s Diseases

Authors: Şerife Ayten, Saniye Bilici

Published in: Current Nutrition Reports

Login to get access

Abstract

Purpose of Review

The gut microbiota plays a crucial role in the pathogenesis of neuroinflammation and Alzheimer’s and Parkinson’s diseases. One of the main modulators of the gut microbiota is the diet, which directly influences host homeostasis and biological processes. Some dietary patterns can affect neurodegenerative diseases’ progression through gut microbiota composition, gut permeability, and the synthesis and secretion of microbial-derived neurotrophic factors and neurotransmitters. This comprehensive review critically assesses existing studies investigating the impact of dietary interventions on the modulation of the microbiota in relation to neurodegenerative diseases and neuroinflammation.

Recent Findings

There are limited studies on the effects of specific diets, such as the ketogenic diet, Mediterranean diet, vegetarian diet, and Western diet, on the progression of neuroinflammation and Alzheimer’s and Parkinson’s diseases through the gut-brain axis. The ketogenic diet displays promising potential in ameliorating the clinical trajectory of mild cognitive impairment and Alzheimer’s disease. However, conflicting outcomes were observed among various studies, highlighting the need to consider diverse types of ketogenic diets and their respective effects on clinical outcomes and gut microbiota composition. Vegetarian and Mediterranean diets, known for their anti-inflammatory properties, can be effective against Parkinson’s disease, which is related to inflammation in the gut environment. On the other hand, the westernization of dietary patterns was associated with reduced gut microbial diversity and metabolites, which ultimately contributed to the development of neuroinflammation and cognitive impairment.

Summary

Various studies examining the impact of dietary interventions on the gut-brain axis with regard to neuroinflammation and Alzheimer’s and Parkinson’s diseases are thoroughly reviewed in this article. A strong mechanistic explanation is required to fully understand the complex interactions between various dietary patterns, gut microbiota, and microbial metabolites and the effects these interactions have on cognitive function and the progression of these diseases.
Literature
1.
go back to reference Feigin VL, et al. The global burden of neurological disorders: translating evidence into policy. Lancet Neurol. 2020;19(3):255–65.PubMedCrossRef Feigin VL, et al. The global burden of neurological disorders: translating evidence into policy. Lancet Neurol. 2020;19(3):255–65.PubMedCrossRef
2.
go back to reference Nichols E, et al. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(1):88–106.CrossRef Nichols E, et al. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(1):88–106.CrossRef
3.
go back to reference Nagpal R, et al. Gut mycobiome and its interaction with diet, gut bacteria and Alzheimer’s disease markers in subjects with mild cognitive impairment: a pilot study. EBioMedicine. 2020;59: 102950.PubMedPubMedCentralCrossRef Nagpal R, et al. Gut mycobiome and its interaction with diet, gut bacteria and Alzheimer’s disease markers in subjects with mild cognitive impairment: a pilot study. EBioMedicine. 2020;59: 102950.PubMedPubMedCentralCrossRef
4.
5.
6.
go back to reference Cekanaviciute E, et al. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci. 2017;114(40):10713–8.PubMedPubMedCentralCrossRef Cekanaviciute E, et al. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci. 2017;114(40):10713–8.PubMedPubMedCentralCrossRef
8.
go back to reference Kumar DKV, et al. Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease. Science Transl Med. 2016;8(340):340ra72-340ra72.CrossRef Kumar DKV, et al. Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease. Science Transl Med. 2016;8(340):340ra72-340ra72.CrossRef
9.
go back to reference Zhuang Z-Q, et al. Gut microbiota is altered in patients with Alzheimer’s disease. J Alzheimer’s Dis. 2018;63(4):1337–46.CrossRef Zhuang Z-Q, et al. Gut microbiota is altered in patients with Alzheimer’s disease. J Alzheimer’s Dis. 2018;63(4):1337–46.CrossRef
10.
go back to reference Saji N, et al. The relationship between the gut microbiome and mild cognitive impairment in patients without dementia: a cross-sectional study conducted in Japan. Sci Rep. 2019;9(1):1–10. Saji N, et al. The relationship between the gut microbiome and mild cognitive impairment in patients without dementia: a cross-sectional study conducted in Japan. Sci Rep. 2019;9(1):1–10.
11.
go back to reference Alkasir R, et al. Human gut microbiota: the links with dementia development. Protein Cell. 2017;8(2):90–102.PubMedCrossRef Alkasir R, et al. Human gut microbiota: the links with dementia development. Protein Cell. 2017;8(2):90–102.PubMedCrossRef
12.
go back to reference •• Nagpal R, et al. Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer’s disease markers in subjects with mild cognitive impairment. EBioMedicine. 2019;47:529–42. According to the research, certain gut microbial signatures may indicate MCI, and MMKD may modulate gut metabolites and microbiome in correlation with enhanced AD biomarkers in CSF.PubMedPubMedCentralCrossRef •• Nagpal R, et al. Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer’s disease markers in subjects with mild cognitive impairment. EBioMedicine. 2019;47:529–42. According to the research, certain gut microbial signatures may indicate MCI, and MMKD may modulate gut metabolites and microbiome in correlation with enhanced AD biomarkers in CSF.PubMedPubMedCentralCrossRef
14.
go back to reference Solas M, et al. Inflammation and gut-brain axis link obesity to cognitive dysfunction: plausible pharmacological interventions. Curr Opin Pharmacol. 2017;37:87–92.PubMedCrossRef Solas M, et al. Inflammation and gut-brain axis link obesity to cognitive dysfunction: plausible pharmacological interventions. Curr Opin Pharmacol. 2017;37:87–92.PubMedCrossRef
15.
go back to reference Rinninella E, et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms. 2019;7(1):14.PubMedPubMedCentralCrossRef Rinninella E, et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms. 2019;7(1):14.PubMedPubMedCentralCrossRef
16.
go back to reference •• Hegelmaier T, et al. Interventional influence of the intestinal microbiome through dietary intervention and bowel cleansing might improve motor symptoms in Parkinson’s disease. Cells. 2020;9(2):376. In PD patients, dietary modification and colon cleansing are acceptable approaches for modifying the gut microbiota and maybe enhancing clinical outcomes.PubMedPubMedCentralCrossRef •• Hegelmaier T, et al. Interventional influence of the intestinal microbiome through dietary intervention and bowel cleansing might improve motor symptoms in Parkinson’s disease. Cells. 2020;9(2):376. In PD patients, dietary modification and colon cleansing are acceptable approaches for modifying the gut microbiota and maybe enhancing clinical outcomes.PubMedPubMedCentralCrossRef
17.
go back to reference Quigley EM. Microbiota-brain-gut axis and neurodegenerative diseases. Curr Neurol Neurosci Rep. 2017;17:1–9.CrossRef Quigley EM. Microbiota-brain-gut axis and neurodegenerative diseases. Curr Neurol Neurosci Rep. 2017;17:1–9.CrossRef
18.
go back to reference Dilmore AH, et al. Effects of a ketogenic and low-fat diet on the human metabolome, microbiome, and foodome in adults at risk for Alzheimer’s disease. Alzheimer’s & Dementia. 2023;19(11):4805–16.CrossRef Dilmore AH, et al. Effects of a ketogenic and low-fat diet on the human metabolome, microbiome, and foodome in adults at risk for Alzheimer’s disease. Alzheimer’s & Dementia. 2023;19(11):4805–16.CrossRef
19.
go back to reference Rusch C, et al. Mediterranean diet adherence in people with Parkinson’s disease reduces constipation symptoms and changes fecal microbiota after a 5-week single-arm pilot study. Front Neurol. 2021;12:794640.PubMedPubMedCentralCrossRef Rusch C, et al. Mediterranean diet adherence in people with Parkinson’s disease reduces constipation symptoms and changes fecal microbiota after a 5-week single-arm pilot study. Front Neurol. 2021;12:794640.PubMedPubMedCentralCrossRef
20.
go back to reference Ma D, et al. Ketogenic diet enhances neurovascular function with altered gut microbiome in young healthy mice. Sci Rep. 2018;8(1):1–10. Ma D, et al. Ketogenic diet enhances neurovascular function with altered gut microbiome in young healthy mice. Sci Rep. 2018;8(1):1–10.
21.
go back to reference Park S, et al. Ketone production by ketogenic diet and by intermittent fasting has different effects on the gut microbiota and disease progression in an Alzheimer’s disease rat model. JCBN. 2020;67(2):188–98. Park S, et al. Ketone production by ketogenic diet and by intermittent fasting has different effects on the gut microbiota and disease progression in an Alzheimer’s disease rat model. JCBN. 2020;67(2):188–98.
22.
go back to reference Chu C, et al. A low-protein, high-carbohydrate diet exerts a neuroprotective effect on mice with 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced Parkinson’s disease by regulating the microbiota-metabolite–brain axis and fibroblast growth factor 21. J Agric Food Chem. 2023;71(23):8877–93.PubMedCrossRef Chu C, et al. A low-protein, high-carbohydrate diet exerts a neuroprotective effect on mice with 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced Parkinson’s disease by regulating the microbiota-metabolite–brain axis and fibroblast growth factor 21. J Agric Food Chem. 2023;71(23):8877–93.PubMedCrossRef
23.
go back to reference Magnusson K, et al. Relationships between diet-related changes in the gut microbiome and cognitive flexibility. Neuroscience. 2015;300:128–40.PubMedCrossRef Magnusson K, et al. Relationships between diet-related changes in the gut microbiome and cognitive flexibility. Neuroscience. 2015;300:128–40.PubMedCrossRef
24.
go back to reference • Saiyasit N, et al. Gut dysbiosis develops before metabolic disturbance and cognitive decline in high-fat diet–induced obese condition. Nutrition. 2020;69:110576. The research shows that a high-fat diet initially leads to gut dysbiosis, which then progresses to brain pathology, resulting in cognitive decline.PubMedCrossRef • Saiyasit N, et al. Gut dysbiosis develops before metabolic disturbance and cognitive decline in high-fat diet–induced obese condition. Nutrition. 2020;69:110576. The research shows that a high-fat diet initially leads to gut dysbiosis, which then progresses to brain pathology, resulting in cognitive decline.PubMedCrossRef
25.
go back to reference Li J-M, et al. Dietary fructose-induced gut dysbiosis promotes mouse hippocampal neuroinflammation: a benefit of short-chain fatty acids. Microbiome. 2019;7(1):1–14.CrossRef Li J-M, et al. Dietary fructose-induced gut dysbiosis promotes mouse hippocampal neuroinflammation: a benefit of short-chain fatty acids. Microbiome. 2019;7(1):1–14.CrossRef
26.
go back to reference Beilharz JE, Maniam J, Morris M. Short-term exposure to a diet high in fat and sugar, or liquid sugar, selectively impairs hippocampal-dependent memory, with differential impacts on inflammation. Behav Brain Res. 2016;306:1–7.PubMedCrossRef Beilharz JE, Maniam J, Morris M. Short-term exposure to a diet high in fat and sugar, or liquid sugar, selectively impairs hippocampal-dependent memory, with differential impacts on inflammation. Behav Brain Res. 2016;306:1–7.PubMedCrossRef
27.
go back to reference Neto J, et al. Impact of cafeteria diet and n3 supplementation on the intestinal microbiota, fatty acids levels, neuroinflammatory markers and social memory in male rats. Physiol Behav. 2023;260:114068.PubMedCrossRef Neto J, et al. Impact of cafeteria diet and n3 supplementation on the intestinal microbiota, fatty acids levels, neuroinflammatory markers and social memory in male rats. Physiol Behav. 2023;260:114068.PubMedCrossRef
28.
go back to reference Shi H, et al. A fiber-deprived diet causes cognitive impairment and hippocampal microglia-mediated synaptic loss through the gut microbiota and metabolites. Microbiome. 2021;9(1):1–20.CrossRef Shi H, et al. A fiber-deprived diet causes cognitive impairment and hippocampal microglia-mediated synaptic loss through the gut microbiota and metabolites. Microbiome. 2021;9(1):1–20.CrossRef
29.
go back to reference Deshpande NG, et al. High fat diet alters gut microbiota but not spatial working memory in early middle-aged Sprague Dawley rats. PLoS ONE. 2019;14(5):e0217553.PubMedPubMedCentralCrossRef Deshpande NG, et al. High fat diet alters gut microbiota but not spatial working memory in early middle-aged Sprague Dawley rats. PLoS ONE. 2019;14(5):e0217553.PubMedPubMedCentralCrossRef
30.
go back to reference Sanguinetti E, et al. Microbiome-metabolome signatures in mice genetically prone to develop dementia, fed a normal or fatty diet. Sci Rep. 2018;8(1):4907.PubMedPubMedCentralCrossRef Sanguinetti E, et al. Microbiome-metabolome signatures in mice genetically prone to develop dementia, fed a normal or fatty diet. Sci Rep. 2018;8(1):4907.PubMedPubMedCentralCrossRef
31.
go back to reference Zhang P, et al. Alterations to the microbiota–colon–brain axis in high-fat-diet-induced obese mice compared to diet-resistant mice. J Nutr Biochem. 2019;65:54–65.PubMedCrossRef Zhang P, et al. Alterations to the microbiota–colon–brain axis in high-fat-diet-induced obese mice compared to diet-resistant mice. J Nutr Biochem. 2019;65:54–65.PubMedCrossRef
32.
go back to reference Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci. 1991;12:383–8.PubMedCrossRef Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci. 1991;12:383–8.PubMedCrossRef
33.
go back to reference Le Page A, et al. Role of the peripheral innate immune system in the development of Alzheimer’s disease. Exp Gerontol. 2018;107:59–66.PubMedCrossRef Le Page A, et al. Role of the peripheral innate immune system in the development of Alzheimer’s disease. Exp Gerontol. 2018;107:59–66.PubMedCrossRef
35.
go back to reference Hajjo H, Geva-Zatorsky N. Gut microbiota–host interactions now also brain-immune axis. Curr Opin Neurobiol. 2020;62:53–9.PubMedCrossRef Hajjo H, Geva-Zatorsky N. Gut microbiota–host interactions now also brain-immune axis. Curr Opin Neurobiol. 2020;62:53–9.PubMedCrossRef
36.
go back to reference Szablewski L. Human gut microbiota in health and Alzheimer’s disease. J Alzheimers Dis. 2018;62(2):549–60.PubMedCrossRef Szablewski L. Human gut microbiota in health and Alzheimer’s disease. J Alzheimers Dis. 2018;62(2):549–60.PubMedCrossRef
37.
go back to reference Junges VM, et al. Crosstalk between gut microbiota and central nervous system: a focus on Alzheimer’s disease. Curr Alzheimer Res. 2018;15(13):1179–90.PubMedCrossRef Junges VM, et al. Crosstalk between gut microbiota and central nervous system: a focus on Alzheimer’s disease. Curr Alzheimer Res. 2018;15(13):1179–90.PubMedCrossRef
38.
go back to reference Bonfili L, et al. Microbiota modulation counteracts Alzheimer’s disease progression influencing neuronal proteolysis and gut hormones plasma levels. Sci Rep. 2017;7(1):2426.PubMedPubMedCentralCrossRef Bonfili L, et al. Microbiota modulation counteracts Alzheimer’s disease progression influencing neuronal proteolysis and gut hormones plasma levels. Sci Rep. 2017;7(1):2426.PubMedPubMedCentralCrossRef
39.
go back to reference Morris MC, Tangney CC. Dietary fat composition and dementia risk. Neurobiol Aging. 2014;35:S59–64.PubMedCrossRef Morris MC, Tangney CC. Dietary fat composition and dementia risk. Neurobiol Aging. 2014;35:S59–64.PubMedCrossRef
41.
go back to reference Gaspard N, et al. New-onset refractory status epilepticus (NORSE) and febrile infection–related epilepsy syndrome (FIRES): state of the art and perspectives. Epilepsia. 2018;59(4):745–52.PubMedCrossRef Gaspard N, et al. New-onset refractory status epilepticus (NORSE) and febrile infection–related epilepsy syndrome (FIRES): state of the art and perspectives. Epilepsia. 2018;59(4):745–52.PubMedCrossRef
42.
go back to reference Tefera TW, Borges K. Metabolic dysfunctions in amyotrophic lateral sclerosis pathogenesis and potential metabolic treatments. Front Neurosci. 2017;10:611.PubMedPubMedCentralCrossRef Tefera TW, Borges K. Metabolic dysfunctions in amyotrophic lateral sclerosis pathogenesis and potential metabolic treatments. Front Neurosci. 2017;10:611.PubMedPubMedCentralCrossRef
43.
go back to reference Prins ML, Matsumoto JH. The collective therapeutic potential of cerebral ketone metabolism in traumatic brain injury. J Lipid Res. 2014;55(12):2450–7.PubMedPubMedCentralCrossRef Prins ML, Matsumoto JH. The collective therapeutic potential of cerebral ketone metabolism in traumatic brain injury. J Lipid Res. 2014;55(12):2450–7.PubMedPubMedCentralCrossRef
44.
go back to reference Suzuki M, et al. Effect of β-hydroxybutyrate, a cerebral function improving agent, on cerebral hypoxia, anoxia and ischemia in mice and rats. Jpn J Pharmacol. 2001;87(2):143–50.PubMedCrossRef Suzuki M, et al. Effect of β-hydroxybutyrate, a cerebral function improving agent, on cerebral hypoxia, anoxia and ischemia in mice and rats. Jpn J Pharmacol. 2001;87(2):143–50.PubMedCrossRef
45.
go back to reference Kashiwaya Y, et al. d-β-Hydroxybutyrate protects neurons in models of Alzheimer’s and Parkinson’s disease. Proc Natl Acad Sci. 2000;97(10):5440–4.PubMedPubMedCentralCrossRef Kashiwaya Y, et al. d-β-Hydroxybutyrate protects neurons in models of Alzheimer’s and Parkinson’s disease. Proc Natl Acad Sci. 2000;97(10):5440–4.PubMedPubMedCentralCrossRef
47.
go back to reference Hirsch L, et al. The incidence of Parkinson’s disease: a systematic review and meta-analysis. Neuroepidemiology. 2016;46(4):292–300.PubMedCrossRef Hirsch L, et al. The incidence of Parkinson’s disease: a systematic review and meta-analysis. Neuroepidemiology. 2016;46(4):292–300.PubMedCrossRef
48.
go back to reference Man WK, et al. The docking of synaptic vesicles on the presynaptic membrane induced by α-synuclein is modulated by lipid composition. Nat Commun. 2021;12(1):927.PubMedPubMedCentralCrossRef Man WK, et al. The docking of synaptic vesicles on the presynaptic membrane induced by α-synuclein is modulated by lipid composition. Nat Commun. 2021;12(1):927.PubMedPubMedCentralCrossRef
49.
go back to reference Yu Q-J, et al. Parkinson disease with constipation: clinical features and relevant factors. Sci Rep. 2018;8(1):1–9. Yu Q-J, et al. Parkinson disease with constipation: clinical features and relevant factors. Sci Rep. 2018;8(1):1–9.
50.
go back to reference Yan F, et al. Gastrointestinal nervous system α-synuclein as a potential biomarker of Parkinson disease. Medicine. 2018;97(28):11337.CrossRef Yan F, et al. Gastrointestinal nervous system α-synuclein as a potential biomarker of Parkinson disease. Medicine. 2018;97(28):11337.CrossRef
51.
52.
go back to reference Keshavarzian A, et al. Colonic bacterial composition in Parkinson’s disease. Mov Disord. 2015;30(10):1351–60.PubMedCrossRef Keshavarzian A, et al. Colonic bacterial composition in Parkinson’s disease. Mov Disord. 2015;30(10):1351–60.PubMedCrossRef
53.
go back to reference Petrov V, et al. Analysis of gut microbiota in patients with Parkinson’s disease. Bull Exp Biol Med. 2017;162:734–7.PubMedCrossRef Petrov V, et al. Analysis of gut microbiota in patients with Parkinson’s disease. Bull Exp Biol Med. 2017;162:734–7.PubMedCrossRef
54.
go back to reference Scheperjans F, et al. Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov Disord. 2015;30(3):350–8.PubMedCrossRef Scheperjans F, et al. Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov Disord. 2015;30(3):350–8.PubMedCrossRef
55.
go back to reference Romano S, et al. Meta-analysis of the Parkinson’s disease gut microbiome suggests alterations linked to intestinal inflammation. npj PD. 2021;7(1):27. Romano S, et al. Meta-analysis of the Parkinson’s disease gut microbiome suggests alterations linked to intestinal inflammation. npj PD. 2021;7(1):27.
56.
go back to reference Haikal C, Chen Q-Q, Li J-Y. Microbiome changes: an indicator of Parkinson’s disease? Transl Neurodegener. 2019;8:1–9.CrossRef Haikal C, Chen Q-Q, Li J-Y. Microbiome changes: an indicator of Parkinson’s disease? Transl Neurodegener. 2019;8:1–9.CrossRef
58.
go back to reference Cuevas E, et al. Tauroursodeoxycholic acid (TUDCA) is neuroprotective in a chronic mouse model of Parkinson’s disease. Nutr Neurosci. 2022;25(7):1374–91.PubMedCrossRef Cuevas E, et al. Tauroursodeoxycholic acid (TUDCA) is neuroprotective in a chronic mouse model of Parkinson’s disease. Nutr Neurosci. 2022;25(7):1374–91.PubMedCrossRef
59.
go back to reference Wang K, et al. Taurine improves neuron injuries and cognitive impairment in a mouse Parkinson’s disease model through inhibition of microglial activation. Neurotoxicology. 2021;83:129–36.PubMedCrossRef Wang K, et al. Taurine improves neuron injuries and cognitive impairment in a mouse Parkinson’s disease model through inhibition of microglial activation. Neurotoxicology. 2021;83:129–36.PubMedCrossRef
60.
go back to reference Kim S, et al. Gram-negative bacteria and their lipopolysaccharides in Alzheimer’s disease: pathologic roles and therapeutic implications. Transl Neurodegener. 2021;10(1):1–23.CrossRef Kim S, et al. Gram-negative bacteria and their lipopolysaccharides in Alzheimer’s disease: pathologic roles and therapeutic implications. Transl Neurodegener. 2021;10(1):1–23.CrossRef
62.
go back to reference Vieira MN, et al. Protein tyrosine phosphatase 1B (PTP1B): a potential target for Alzheimer’s therapy? Frontiers Aging Neurosci. 2017;9:7.CrossRef Vieira MN, et al. Protein tyrosine phosphatase 1B (PTP1B): a potential target for Alzheimer’s therapy? Frontiers Aging Neurosci. 2017;9:7.CrossRef
Metadata
Title
Modulation of Gut Microbiota Through Dietary Intervention in Neuroinflammation and Alzheimer’s and Parkinson’s Diseases
Authors
Şerife Ayten
Saniye Bilici
Publication date
23-04-2024
Publisher
Springer US
Published in
Current Nutrition Reports
Electronic ISSN: 2161-3311
DOI
https://doi.org/10.1007/s13668-024-00539-7
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.